AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12358335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 65
Study 10076146 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (100 microg single dose)
Number of subjects: 694
Study 10076146 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (standard 8-hour infusion)
Number of subjects: 694
Study 7572651 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (1 mg intravenous, followed by oral therapy)
Number of subjects: 43
Study 7572651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7572651 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 43
Study 2404556 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and heparin; 1 g 5-FU and 5000 U heparin daily for 7 days
Number of subjects: 304
Study 2404556 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase; 10,000 U/hour for 24 hours
Number of subjects: 304
Study 2404556 — intervention group
Group type: COMPARATOR
Intervention: Control group; surgery alone
Number of subjects: 304
Study 6102865 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclofos 70 mg kg‐1 + atropine 0.03 mg kg‐1
Number of subjects: 128
Study 6102865 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg kg‐1 + atropine 0.03 mg kg‐1
Number of subjects: 128
Study 6102865 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.02 mg kg‐1 + atropine 0.03 mg kg‐1
Number of subjects: 128
Study 6102865 — intervention group
Group type: COMPARATOR
Intervention: All drugs (Triclofos, Diazepam, Flunitrazepam)
Number of subjects: 128
Study 6102865 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclofos 70 mg kg‐1
Number of subjects: 128
Study 6102865 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg kg‐1 and Flunitrazepam 0.02 mg kg‐1
Number of subjects: 128
Study 6102865 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (Diazepam and Flunitrazepam)
Number of subjects: 128
Study 31797310 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding ACEIs/ARBs
Number of subjects: 430
Study 31797310 — intervention group
Group type: COMPARATOR
Intervention: Continue/start ACEIs/ARBs
Number of subjects: 430
Study 29790913 — intervention group
Group type: EXPERIMENTAL
Intervention: Program 3 (most intensive ASP intervention)
Number of subjects: 15
Study 29790913 — intervention group
Group type: COMPARATOR
Intervention: Program 1 and 2
Number of subjects: 15
Study 29790913 — intervention group
Group type: COMPARATOR
Intervention: Program 3 vs Program 1 and 2
Number of subjects: 15
Study 27415612 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin (R group, n=26)
Number of subjects: 50
Study 27415612 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin plus 2 g of ω-3 PUFAs (R + O group, n=24)
Number of subjects: 50
Study 27415612 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 50
Study 24553480 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral syrup containing paracetamol, phenylephrine hydrochloride, and guaifenesin
Number of subjects: 45
Study 24553480 — intervention group
Group type: COMPARATOR
Intervention: Reference oral liquid formulation
Number of subjects: 45
Study 24553480 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral syrup
Number of subjects: 45
Study 22442826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 10 mg
Number of subjects: 13
Study 22442826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 25 mg
Number of subjects: 13
Study 22442826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 13
Study 22442826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (all doses)
Number of subjects: 13
Study 22442826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 20980796 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX® (zoster vaccine) administered concomitantly with PNEUMOVAX® 23 (pneumococcal vaccine)
Number of subjects: 473
Study 20980796 — intervention group
Group type: COMPARATOR
Intervention: PNEUMOVAX® 23 (pneumococcal vaccine) administered concomitantly with ZOSTAVAX®
Number of subjects: 473
Study 20980796 — intervention group
Group type: COMPARATOR
Intervention: ZOSTAVAX® (zoster vaccine) administered nonconcomitantly with PNEUMOVAX® 23 (pneumococcal vaccine)
Number of subjects: 473
Study 18508290 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 5 mg once daily
Number of subjects: 110
Study 18508290 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 12.5 mg once daily
Number of subjects: 110
Study 18508290 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 25 mg once daily
Number of subjects: 110
Study 18508290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 16402635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 69
Study 16402635 — intervention group
Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 69
Study 12635061 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg/min (group 1, n = 23)
Number of subjects: 72
Study 12635061 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 microg/kg/min (group 2, n = 24)
Number of subjects: 72
Study 12635061 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 3 microg/kg/min (group 3, n = 25)
Number of subjects: 72
Study 12635061 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5%‐1% inspired) as a rescue anesthetic
Number of subjects: 72
Study 12635061 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (2‐4 microg/kg/min) with isoflurane supplementation
Number of subjects: 72
Study 12635061 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil continuous infusions (1‐5 microg/kg/min)
Number of subjects: 72
Study 12635061 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative extubation criteria
Number of subjects: 72
Study 10979946 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF (400 microg/m(2), day on days 1‐90) with ATG, CyA, and DAN
Number of subjects: 119
Study 10979946 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG, CyA, DAN, and rhG‐CSF
Number of subjects: 119
Study 10979946 — intervention group
Group type: COMPARATOR
Intervention: ATG, CyA, and DAN without rhG‐CSF
Number of subjects: 119
Study 8774389 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled smoking
Number of subjects: 25
Study 8774389 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 25
Study 1734554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampons impregnated with tranexamic acid (TA), one tampon inserted
Number of subjects: 19
Study 1734554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampons impregnated with tranexamic acid (TA), three tampons administered at 2-hourly intervals over 6 hours
Number of subjects: 19
Study 6429705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 100
Study 6429705 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 100
Study 30724356 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feeding
Number of subjects: 114
Study 30724356 — intervention group
Group type: COMPARATOR
Intervention: Enteral feeding
Number of subjects: 114
Study 30005608 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Literacy Questionnaire (HLQ)
Number of subjects: 0
Study 25818246 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy
Number of subjects: 1133
Study 25436480 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment for simple bone cysts (exact intervention details not provided)
Number of subjects: 24
Study 25436480 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment for simple bone cysts
Number of subjects: 24
Study 22437191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus BMX 54 (vaginal application, one tablet once a week for 12 weeks)
Number of subjects: 60
Study 22437191 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 60
Study 20507810 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral slow-release fluoride glass devices
Number of subjects: 20
Study 20507810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral slow-release fluoride glass devices
Number of subjects: 20
Study 20507810 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (five glass beads)
Number of subjects: 20
Study 20507810 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (five fluoride devices with plastic brackets facing down)
Number of subjects: 20
Study 20507810 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (five fluoride devices with plastic brackets facing up)
Number of subjects: 20
Study 20507810 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study 18327969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of anesthetic solution
Number of subjects: 32
Study 18327969 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of anesthetic solution
Number of subjects: 32
Study 15983312 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 328
Study 15983312 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous regular insulin
Number of subjects: 328
Study 12797909 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-Inhibitors (group 1)
Number of subjects: 42
Study 12797909 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (group 2)
Number of subjects: 42
Study 12797909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-Antagonists (group 3)
Number of subjects: 42
Study 12797909 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 0)
Number of subjects: 42
Study 10334671 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of haemoglobin (target 13.5-16.0 g/dl)
Number of subjects: 1942
Study 10334671 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of haemoglobin (target 13.0-14.0 g/dl)
Number of subjects: 1942
Study 10334671 — intervention group
Group type: EXPERIMENTAL
Intervention: Target haematocrit 42%
Number of subjects: 1942
Study 10334671 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase haemoglobin to a mean of 12.5 g/dl
Number of subjects: 1942
Study 10334671 — intervention group
Group type: COMPARATOR
Intervention: Control group (target haemoglobin 9.5-10.5 g/dl)
Number of subjects: 1942
Study 10334671 — intervention group
Group type: COMPARATOR
Intervention: Control group (target haematocrit 30%)
Number of subjects: 1942
Study 8729309 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (0.3 mg subcutaneous) on demand (group 1, n = 20)
Number of subjects: 60
Study 8729309 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)‐propacetamol (2 g)‐ketoprofen (100 mg) by intravenous route over 2 hours followed by an infusion of propacetamol (2 g) and ketoprofen (100 mg) at a constant rate over 22 hours (group 2, n = 20)
Number of subjects: 60
Study 8729309 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of buprenorphine (0.3 mg), propacetamol (2 g) and ketoprofen (100 mg) over the same period (group 3, n = 20)
Number of subjects: 60
Study 1877449 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated dual-chamber pacing (DDD)
Number of subjects: 0
Study 1877449 — intervention group
Group type: COMPARATOR
Intervention: Simulated single-chamber pacing (VVI)
Number of subjects: 0
Study 6145288 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 6145288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30310979 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Cryotherapy (WBC) - 3 and 4 min at -85 °C
Number of subjects: 24
Study 30310979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) - 10 min at 10 °C
Number of subjects: 24
Study 30310979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 29800066 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-support intervention
Number of subjects: 61
Study 29800066 — intervention group
Group type: EXPERIMENTAL
Intervention: English-only intervention
Number of subjects: 61
Study 29800066 — intervention group
Group type: COMPARATOR
Intervention: Spanish-support control
Number of subjects: 61
Study 29800066 — intervention group
Group type: COMPARATOR
Intervention: English-only control
Number of subjects: 61
Study 27386642 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiguanjian Decoction (YD) combined with Adefovir Dipivoxil Tablet (ADT)
Number of subjects: 68
Study 27386642 — intervention group
Group type: COMPARATOR
Intervention: Adefovir Dipivoxil Tablet (ADT) alone
Number of subjects: 68
Study 24268670 — intervention group
Group type: EXPERIMENTAL
Intervention: Targon FN
Number of subjects: 52
Study 24268670 — intervention group
Group type: COMPARATOR
Intervention: SHS
Number of subjects: 52
Study 19363197 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective frequency ratings from Group 1
Number of subjects: 144
Study 19363197 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective frequency ratings from Group 2
Number of subjects: 144
Study 19363197 — intervention group
Group type: EXPERIMENTAL
Intervention: Imageability ratings from Group 1
Number of subjects: 144
Study 19363197 — intervention group
Group type: EXPERIMENTAL
Intervention: Imageability ratings from Group 2
Number of subjects: 144
Study 19363197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ratings from both groups
Number of subjects: 144
Study 12520748 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP regimen (mitomycin + ifosfamid + cisplatin)
Number of subjects: 92
Study 12520748 — intervention group
Group type: EXPERIMENTAL
Intervention: TP regimen (Taxol + cisplatin)
Number of subjects: 92
Study 12520748 — intervention group
Group type: EXPERIMENTAL
Intervention: DP regimen (docetaxel + cisplatin)
Number of subjects: 92
Study 9220875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management strategies and medications at hospital admission
Number of subjects: 959
Study 9220875 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antiseptics vs cleansing solutions
Number of subjects: 959
Study 9220875 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of non-recommended treatments for ulcers
Number of subjects: 959
Study 9220875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain control and ulcer management
Number of subjects: 959
Study 8193690 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 125000
Study 8193690 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC vaccine
Number of subjects: 125000
Study 3812345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest selenium quintile (< 105.0 micrograms/L)
Number of subjects: 10
Study 3812345 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched cohort members alive at the end of 1983)
Number of subjects: 10
Study 30153780 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 50
Study 30153780 — intervention group
Group type: COMPARATOR
Intervention: Histamine-2 Receptor Blockers (H2RB)
Number of subjects: 50
Study 26909479 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate per day for 4 months)
Number of subjects: 84
Study 26909479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 24552184 — intervention group
Group type: EXPERIMENTAL
Intervention: IN.PACT Amphirion™ paclitaxel drug-eluting balloon (IA-DEB)
Number of subjects: 358
Study 24552184 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon angioplasty (PTA)
Number of subjects: 358
Study 22681643 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral sparing intensity modulated radiation therapy (US‐IMRT)
Number of subjects: 16
Study 22681643 — intervention group
Group type: COMPARATOR
Intervention: Standard intensity modulated radiation therapy (S‐IMRT)
Number of subjects: 16
Study 20836856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based Internet mediated intervention
Number of subjects: 0
Study 17667137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac
Number of subjects: 90
Study 17667137 — intervention group
Group type: COMPARATOR
Intervention: Oral mefenamic acid and intramuscular meperidine
Number of subjects: 90
Study 15126522 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 microg FSH-CTP
Number of subjects: 98
Study 15126522 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 microg FSH-CTP
Number of subjects: 98
Study 15126522 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 microg FSH-CTP
Number of subjects: 98
Study 15126522 — intervention group
Group type: COMPARATOR
Intervention: 150 IU rFSH (control)
Number of subjects: 98
Study 15126522 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH-CTP groups
Number of subjects: 98
Study 15126522 — intervention group
Group type: COMPARATOR
Intervention: rFSH group (control)
Number of subjects: 98
Study 11452896 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg slow release dipyridamole (DP)
Number of subjects: 6602
Study 11452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA plus DP
Number of subjects: 6602
Study 11452896 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 25 mg acetylsalicylic acid (ASA)
Number of subjects: 6602
Study 11452896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study 9729596 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 kcal exercise session
Number of subjects: 11
Study 9729596 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,300 kcal exercise session
Number of subjects: 11
Study 9729596 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 kcal exercise session
Number of subjects: 11
Study 9729596 — intervention group
Group type: COMPARATOR
Intervention: 800 kcal exercise session
Number of subjects: 11
Study 7920874 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Centre group (RC group) - three-week in-patient weight reduction programme
Number of subjects: 52
Study 7920874 — intervention group
Group type: COMPARATOR
Intervention: Health Centre group (HC group) - ten-week out-patient weight reduction course
Number of subjects: 52
Study 3288723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pentobarbital
Number of subjects: 73
Study 3288723 — intervention group
Group type: COMPARATOR
Intervention: Control regimen without pentobarbital
Number of subjects: 73
Study 31657275 — intervention group
Group type: EXPERIMENTAL
Intervention: High DCI content group (550 mg MYO + 300 mg DCI daily)
Number of subjects: 11
Study 31657275 — intervention group
Group type: COMPARATOR
Intervention: Low DCI content group (550 mg MYO + 27.6 mg DCI daily)
Number of subjects: 11
Study 30019528 — intervention group
Group type: EXPERIMENTAL
Intervention: dHACA (dehydrated human amnion and chorion allograft) applied weekly for up to 12 weeks
Number of subjects: 80
Study 30019528 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard of care) alone
Number of subjects: 80
Study 30019528 — intervention group
Group type: EXPERIMENTAL
Intervention: dHACA (dehydrated human amnion and chorion allograft)
Number of subjects: 80
Study 30019528 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 80
Study 28526171 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) disc dressing
Number of subjects: 101
Study 28526171 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB) disc dressing
Number of subjects: 101
Study 28526171 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101
Study 25632150 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 15
Study 25632150 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study 24265819 — intervention group
Group type: COMPARATOR
Intervention: Standard doses group (20 μg IM at months 0, 1, and 6)
Number of subjects: 132
Study 24265819 — intervention group
Group type: EXPERIMENTAL
Intervention: Four doses group (20 μg IM at months 0, 1, 2, 6)
Number of subjects: 132
Study 24265819 — intervention group
Group type: EXPERIMENTAL
Intervention: Four double doses group (40 μg IM at months 0, 1, 2, 6)
Number of subjects: 132
Study 24265819 — intervention group
Group type: EXPERIMENTAL
Intervention: Four double doses group
Number of subjects: 132
Study 21943318 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement control exercise
Number of subjects: 106
Study 21943318 — intervention group
Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 106
Study 18316660 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school soccer program
Number of subjects: 21
Study 18316660 — intervention group
Group type: COMPARATOR
Intervention: After-school health education program
Number of subjects: 21
Study 17136943 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate plus protein drink (6% CHO, 1.5% protein)
Number of subjects: 13
Study 17136943 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-only drink (6% CHO)
Number of subjects: 13
Study 17136943 — intervention group
Group type: COMPARATOR
Intervention: Water (WA)
Number of subjects: 13
Study 12752347 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 27
Study 12752347 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 27
Study 10877734 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of rofecoxib, 250 mg
Number of subjects: 75
Study 10877734 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of indomethacin, 75 mg
Number of subjects: 75
Study 10877734 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of rofecoxib, 12.5 mg/d
Number of subjects: 75
Study 10877734 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of rofecoxib, 25 mg/d
Number of subjects: 75
Study 10877734 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of indomethacin, 50 mg three times daily
Number of subjects: 75
Study 10877734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9106016 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 3-day course (10 mg/kg daily)
Number of subjects: 371